A pilot study with ethyl bis (2,2-dimethyl-1-aziridinyl) phosphinate (AB-163) and radiation therapy.

[1]  B. Amendola,et al.  Radiation Therapy for Esophageal Cancer: The Medical College of Virginia Experience , 1980, Southern medical journal.

[2]  G. Wampler,et al.  Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163). , 1979, International journal of radiation oncology, biology, physics.

[3]  M. Elkind.  Fundamental questions in the combined use of radiation and chemicals in the treatment of cancer. , 1979, International journal of radiation oncology, biology, physics.

[4]  J. A. Dunn,et al.  Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents. , 1979, International journal of radiation oncology, biology, physics.

[5]  I. Wodinsky,et al.  Combined therapy with an aziridine derivative NSC 200724 (AB182) and radiation on an experimental leukemia. , 1979, International Journal of Radiation Oncology, Biology, Physics.

[6]  J. Fowler,et al.  Hypoxic cell sensitizers: early or late in fractionated therapy? , 1978, British Journal of Cancer.

[7]  V. Marcial.  Carcinoma of the cervix. Present status and future , 1977, Cancer.

[8]  G. Wampler,et al.  Synthfsis of bis(aziridinyl)phosphinyl-N-hydroxyurethane derivatives as antineoplastic agents. , 1975, Journal of medicinal chemistry.

[9]  W. Regelson,et al.  Laboratory and clinical evaluation of the radiation-potentiating activity of ethyl-N-bis (2,2-dimethylethylamidinophosphoro) carbamate (AB-132). , 1975, Journal of medicine.

[10]  S. Levitt,et al.  Effectiveness of radiation therapy in the treatment of carcinoma of the esophagus. A retrospective study. , 1970, The American journal of roentgenology, radium therapy, and nuclear medicine.

[11]  A. Munson,et al.  Studies on the chemistry, antitumor activity, and pharmacology of ethyl Di‐(2,2 ‐dimethyl)ethylenamido phosphate (AB‐163) , 1969, Journal of surgical oncology.

[12]  A. Munson,et al.  Synthesis and chemotherapeutic effects of ethyl bis-(2,2-dimethyl)-ethylenamido phosphate. A preliminary report. , 1967, Journal of pharmaceutical sciences.

[13]  J. Webster,et al.  Combined use of AB‐132 (Meturedepa, Turloc) and X irradiation in the management of advanced bronchogenic carcinoma , 1964, Cancer.

[14]  B. Ma,et al.  Treatment of carcinoma of the head and neck with AB-132 and radiation. , 1962 .